Liou JM et al. |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. |
2018 |
Gastroenterology |
pmid:29964036
|
Kwofie SK et al. |
Screening of Isocitrate Lyase for Novel Anti-Buruli Ulcer Natural Products Originating from Africa. |
2018 |
Molecules |
pmid:29954088
|
Tanabe H et al. |
Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. |
2018 |
Ann. Clin. Microbiol. Antimicrob. |
pmid:29950163
|
Sandri A et al. |
Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice. |
2018 |
Virulence |
pmid:29938577
|
Gonzalez-Hormazabal P et al. |
Prevalence of clarithromycin resistance in Helicobacter pylori in Santiago, Chile, estimated by real-time PCR directly from gastric mucosa. |
2018 |
BMC Gastroenterol |
pmid:29925321
|
|
Clarithromycin in patients with coronary artery disease. |
2018 |
Med Lett Drugs Ther |
pmid:29913468
|
Li M et al. |
Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. |
2018 |
Helicobacter |
pmid:29873436
|
Fiorini G et al. |
Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice. |
2018 |
Eur J Gastroenterol Hepatol |
pmid:29481383
|
Talarico S et al. |
High prevalence of Helicobacter pylori clarithromycin resistance mutations among Seattle patients measured by droplet digital PCR. |
2018 |
Helicobacter |
pmid:29480566
|
Takemori N et al. |
A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report. |
2018 |
J Med Case Rep |
pmid:29454372
|
Xu R et al. |
Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. |
2018 |
Eur. J. Clin. Pharmacol. |
pmid:29453492
|
Tsutsui A et al. |
Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. |
2018 |
J. Infect. Chemother. |
pmid:29428566
|
Tarhini M et al. |
First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy. |
2018 |
Microb. Pathog. |
pmid:29428426
|
Redondo JJ et al. |
A novel RT-PCR for the detection of Helicobacter pylori and identification of clarithromycin resistance mediated by mutations in the 23S rRNA gene. |
2018 |
Diagn. Microbiol. Infect. Dis. |
pmid:29111147
|
Iwamoto J et al. |
Effects of the Concomitant Use of Low-dose Clarithromycin with an Anti-TNFα Antibody in a Patient with Intestinal Behçet Disease. |
2018 |
Intern. Med. |
pmid:29093413
|
Ersoy B et al. |
The anti-inflammatory effects of erythromycin, clarithromycin, azithromycin and roxithromycin on histamine-induced otitis media with effusion in guinea pigs. |
2018 |
J Laryngol Otol |
pmid:29888693
|
Inagaki Y et al. |
Disseminated Cutaneous Infection of Mycobacterium colombiense in a Patient with Myelodysplastic Syndrome. |
2018 |
Intern. Med. |
pmid:29093379
|
De Francesco V et al. |
Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study. |
2018 |
Dig Liver Dis |
pmid:29089267
|
Cerqueira RM et al. |
Cumulative Helicobacter Pylori Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery. |
2018 |
Obes Surg |
pmid:29076008
|
Ullah S et al. |
Hydrophilically modified self-assembling α-tocopherol derivative as niosomal nanocarrier for improving clarithromycin oral bioavailability. |
2018 |
Artif Cells Nanomed Biotechnol |
pmid:28541761
|